Sign In
Buy STOK
$28.86
-1.18 (-3.93%)
At Close: Jul 31, 2026
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
01:00pm, Wednesday, 16'th Aug 2023
Developmental biotechs can deliver outstanding returns for risk-tolerant investors. Wall Street is exceptionally bullish on Stoke Therapeutics, a clinical-stage company developing RNA-based medicines.
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates
09:53am, Monday, 07'th Aug 2023
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to loss of $0.63 per share a year ago.
Why Shares of Stoke Therapeutics Plummeted Tuesday
02:32pm, Tuesday, 25'th Jul 2023
Stoke Therapeutics' shares hit a 52-week low on Tuesday. The company is testing STK-001 to treat Dravet syndrome, a progressive genetic epilepsy disorder.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?
05:48am, Wednesday, 21'st Jun 2023
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be
Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?
10:57am, Wednesday, 14'th Jun 2023
Stoke Therapeutics, Inc. (STOK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, STOK's 50-day simple moving average crossed a
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%
11:27am, Tuesday, 09'th May 2023
The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Thursday, 04'th May 2023
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.66 per share a year ago.
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
08:00am, Wednesday, 03'rd May 2023
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
09:47am, Monday, 06'th Mar 2023
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
04:30pm, Monday, 27'th Feb 2023
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit
Stoke Therapeutics Looks Unfairly Valued
05:17am, Sunday, 12'th Feb 2023
STOK went down steadily over the past two years. Its derisking Dravet data did not help either.
Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
07:30am, Tuesday, 29'th Nov 2022
BEDFORD, Mass.--( BUSINESS WIRE )--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w
Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet Syndrome
06:38am, Monday, 28'th Nov 2022
On Nov 14, Stoke Therapeutics reported interim data from their p1/2 trials in Dravet Syndrome, a severe and progressive genetic epilepsy. Since the news, the stock has declined 41%, from $12.49 on Nov
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Monday, 14'th Nov 2022
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st
